Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

130 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

67 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT04626518 2025-07-25

KEYMAKER-U03

Phase 1/2 Active not recruiting

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

126 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT03516981 2025-07-01

MK-3475-495

Phase 2 Completed

245 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

Clinical Trials

Keynote B59

MK-3475-587

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

MK-3475-06B

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

CLEAR

CheckMate 9DW

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

KEYNOTE-365

MK-3475-03A

MK-6482-043

LEAP-003

KEYNOTE-B98

LEAP-002

LEAP-006

LEAP-011

MK-7902-017

LEAP-001

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

TREMENDOUS-2

LEAP-003

MK-6482-010

LEAP-012

MK-7902-014

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

LEAP-009

KEYNOTE-B61

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

KEYMAKER-U02

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

ALIVE

MK-4830-001

E7080-G000-231

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

LEAP-006

PIERCE

KEYMAKER-U02

KEYMAKER-U02

KEYVIBE-005

LIVIGNO-1

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

KEYMAKER-U03

KEYNOTE-B99

MK-3475-495